Targeted treatments for lung cancer

Monday 08 April 2019, Royal Marsden Hospital London

Description: In this course I describe the faulty genes, pathways and proteins that drive small cell and non-small cell lung cancer. I also explain the scientific rationale behind targeted treatments in use and in development for these diseases, including the progress made with checkpoint inhibitors such as nivolumab, pembrolizumab and durvalumab. Other treatments covered include inhibitors of EGFR, ALK, ROS1, B-Raf, HER2, MET, FGFR and Trk proteins, and angiogenesis inhibitors.

Audience: Ideal for pharmacists, research nurses, pharmaceutical companies, junior doctors or anyone who has been on one of my other courses. Requires a basic understanding of cancer genetics and cancer cell biology.

To book, contact:, or call: 020 7808 2922

Programme summary:

Introduction to lung cancer: a disease of many layers
Targeted treatments for non-small cell lung cancer – part 1
Immunotherapy approaches for lung cancer & current trials
  • Introduction to T cells and checkpoint proteins
  • Mechanism of action of checkpoint inhibitors (CTLA-4, PD-1 and PD-L1 monoclonal antibodies)
  • Overview of the major clinical trials to date
  • Biomarker development
Targeted treatments for non-small cell lung cancer – part 2

Targeted treatments for breast cancer

Thursday 25 May 2017, Christie Hospital Manchester

1-day course: Targeted Treatments for Breast Cancer

Level: Intermediate

Description: This study day will describe many different faulty processes that drive the growth and spread of breast cancer. It will also introduce the science behind a plethora of licensed and yet-to-be licensed breast cancer treatments such as HER2-targeted therapies, PARP inhibitors and CDK inhibitors. To set the scene, the science behind standard treatments such as chemotherapy, radiotherapy and hormone therapy will be explained.

Audience: Ideal for research nurses, clinical nurse specialists, administrative staff, clinical trials coordinators

To book, contact: or call: 0161 446 3403


Cancer cell biology & genetics – key concepts:
The cellular and molecular makeup of breast cancer
The science behind cancer treatments
Targeted treatments for breast cancer
More targeted treatments for breast cancer
  • BRCA genes & PARP inhibitors
  • CDK inhibitors e.g. palbociclib
  • New targets for triple-negative/basal-like breast cancer
  • Immunotherapy for breast cancer

A beginner’s guide to immunotherapy

Wednesday 05 June 2019, Royal Marsden Hospital, London

Level: Intermediate

Audience: Ideal for anyone with an A level or equivalent understanding of cell biology and genetics and who works with cancer patients, data or treatments.

Description: In this half-day course (repeated Morning and afternoon) I describe the logic behind many immunotherapy-based cancer treatments such as checkpoint inhibitors (ipilimumab, pembrolizumab, nivolumab, atezolizumab, durvalumab), adoptive cell transfer (CAR T cell therapy, infiltrating T cells), and vaccine-based treatments (peptide and DNA vaccines, oncolytic viruses, dendritic cell vaccines).

To book, contact: or call: 020 7808 2922


The relationship between cancer and the immune system
Introduction to checkpoint inhibitors
Introduction to adoptive cell transfer methods
Introduction to vaccine-based treatments

Promising Results for New Antibody Drug in Non-Small Cell Lung Cancer Patients


ECC 2013 Press Release: Promising Results for New Antibody Drug in Non-Small Cell Lung Cancer Patients: Smokers Respond Well | ESMO.

Today is the final day of the European Cancer Conference in Amsterdam. The organisers have released a stream of press releases to coincide with the conference, which you can browse here:

However I just wanted to pick out one, which describes recent results with one of a new group of antibody treatments that block the interaction between PD-L1 and PD-1.

As they explain in the press release:

“The programmed death 1 protein PD-1 and its signalling molecule (or ligand) PD-L1 prevent the body’s immune system from attacking and killing cancer cells and this allows the cancer to spread.

However, the anti-PD-L1 monoclonal antibody, MPDL3280A, works by blocking the interaction between PD-L1 and the immune system, thereby boosting a patient’s anti-cancer immune response.

The same news is covered on Medscape:

New Immunotherapy Could Be ‘Game Changer’ in NSCLC.

One of the most exciting aspects of the news is the discovery that benefits smokers and ex-smokers – people who are highly unlikely to have cancers that will respond to EGF-R inhibitors (Iressa & Tarceva) or ALK inhibitors (Zalkori).